Cecilia Brown

Lung Cancers Today

The US Food and Drug Administration (FDA) has approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
The recommended durvalumab dose is 1,500 mg every four weeks for patients with a body weight of ≥30 kg and 20 mg/kg every four weeks for patients with a body weight of &lt;30 kg until disease progression or unacceptable toxicity or a maximum of 24 months, according to the FDA.
Investigators evaluated the efficacy of durvalumab in the randomized, double-blind, placebo-controlled ADRIATIC trial. The trial included 730 patients with LS-SCLC whose disease had not progressed following concurrent platinum-based chemotherapy and radiation therapy. Study investigators randomized patients 1:1:1 to receive single-agent durvalumab, durvalumab plus tremelimumab, or placebo.
The primary efficacy outcome measures of the ADRIATIC trial were overall survival (OS) and progression-free survival (PFS) to compare single-agent durvalumab and placebo, as assessed by blinded independent central review.
Patients who received durvalumab had a median OS of 55.9 months (95% CI, 37.3 to not reached), significantly higher than the median OS of 33.4 months (95% CI, 25.5 to 39.9) in patients who received placebo (hazard ratio, 0.73; 95% CI, 0.57-0.93; P=.0104). Durvalumab also showed a statistically significant PFS (median PFS, 16.6 months; 95% CI, 10.2-28.2) compared to placebo (median PFS, 9.2 months; 95% CI, 7.4-12.9). The hazard ratio for PFS was 0.76 (95% CI, 0.61-0.95; P=.0161).
The most common adverse reactions, occurring in ≥20%, were pneumonitis or radiation pneumonitis and fatigue, according to the FDA.
Source: <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-limited-stage-small-cell-lung-cancer?utm_medium=email&amp;utm_source=govdelivery">FDA</a>

HARMONi-2 Interim Analysis: Ivonescimab Shows PFS Improvements Over Pembrolizumab in NSCLC

Immunotherapy in NSCLC

Stephen V. Liu, MD

Stephen Liu, MD, on Key Debates in NSCLC

Non-Small Cell Lung Cancer

How Frequent Is Suture-Line Recurrence After Surgery for Early-Stage NSCLC?

CROWN 5-Year Subgroup Analysis Shows PFS Is Consistent With Overall Patient Population

ALK+ NSCLC

Can Systematic Immune Inflammation Predict Survival in Patients Receiving Immune Checkpoint Inhibitors for NSCLC?

LUPER Study Evaluates Lurbinectedin Plus Pembrolizumab in Relapsed SCLC

Small Cell Lung Cancer

Latest News

FDA Approves Durvalumab For Limited-Stage Small Cell Lung Cancer

The US Food and Drug Administration (FDA) has approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC).